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Results: Assessment of remodelling deformation in the LAD distribution (n=Z) revealed 
an increase in wall thickness (E33=0.14. 0.16) and the range of transverse shears (E13. 
E23) from 4.02 to ~0.1. resulting in net increase in tissue volume (product of stretch 
ratios: 1.21, 1.04). lmmunohistochemistry revealed evidence of UPA transfection in the 
LAD distribution (n=i), and an increase in type I collagen degradation in the LAD distrfbu- 
tion, compared with the LCx distribution (n=2). No increase in type I collagen degradation 
was observed in both the LAD and LCx distribution of the pig in which )?-galactosidase 
gene was delivered (n=l). 
Conclusion: Results from this ongoing study indicate that UPA induces extracellular 
matrix degradation, yielding altered ventricular remodelling. 
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Zarnegar, Matthew Lyons, Elizabeth M. McNally, University of Chicago, Chicago, IL 
Background: In humans and mice, sarcoglycan gene mutations cause cardiomyopathy 
and muscular dystrophy characterized by focal cardiac necrosis, cardiomyopathy and 
vasospasm. Mice engineered to lack y-sarcoglycan show evidence of cardiomyopathy, 
but the contribution of vasospasm to this pathology is unknown. 
Methods: Smooth muscle tissues of ysarcoglycan mutant mice were studied by immun- 
ofluorascence and immunoblotting. Microvascular filling was used to evaluate vasos- 
pasm. ysarcoglycan mutant mice (n=lO) were treated with oral verapamil at 1 mg/kgiday 
for 5 months. Treated and untreated ysarcoglycan mutant mice were compared by tran- 
sthoracic echocardiography, ambulatory telemetry. histopathotogy, and microvascular 
filling analysis. 
Results: Microvascular filling of psarcoglycan mutant mice showed focal stenoses con- 
sistent with vasospasm. yet the sarcoglycan complex was not perturbed in vascular 
smooth muscle in ysarcoglycan mutant mice. These data indicate that vasospasm 
develops as a secondary consequence of intrinsic cardiomyocyte degeneration. Vera- 
pamil treatment to reduce secondary vasospasm in ysarcoglycan mutant mice attenu- 
ated mywardial fibrosis. Membrane permeability defects were present but reduced in 
verapamil-treated hearts. Verapamil-treated y-sarcoglycan mice had improved lefl ven- 
tricular fractional shortening (44.3% treated vs. 37.4% untreated), improved maximal 
velocity at the aortic outflow tract (114.9 vs. 92.6 cm/s. ~~0.05) and improved cardiac 
index (1.06 vs. 0.67 mllminig, p<O.OOl) compared to untreated mice. 
Conclusions: These data indicate that secondary, not primary, vasospasm contributes 
to cardiomyopathy progression in sarcoglycan gene mutations. Moreover, verapamil can 
reduce secondary vasospasm and limit the progression of cardiomyopathy. 
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Wolfaana C. Poller, Henry Fechner, Xiaomin Wang, Dick Dekkers, Jos Lamer% 
University Hospital Benjamin Franklin, Berlin, Germany, Erasmus Universiteit Rotterdam, 
Rotterdam, The Netherlands 
Background: Impaired sarcoplasmic reticulum Ca2+ pump (SERCAP) activrty plays an 
important role in the development of diastolic dysfunction of the failing heart. Genetic 
complementation experiments in MLP-I- x PL-/- knock out mice, and other data, suggest 
that the expression ratlo of PL to SERCAP may be a target for the improvement of dias- 
tolic dysfunction in the failing heart. Previously we have developed PL-antisense-RNA 
strategies using either a consfitutive CMV or an endothelin-l-inducible ANF promoter. 
External control of applied vectors in viva can not be achieved using these systems. We 
report here on the application of a tetracycline (Tat)-inducible promotor to create vectors 
allowing “exogenous activation” by a drug. Methods and Results: In order to reduce 
background activation of the transgenes. PL-antisense-RNA (Plas) and PL-sense-mRNA 
(PLs) used as control, respectively, were cloned downstream of a Tetracyclin Response 
Element (TRE) in a first vector (AdSTRE-PLas). A second vector (Ads-rtTA) expresses a 
reverse tetracyclin Transactivator (rtTA). Analogous two-vector systems were developed 
for luciferase (Luc). The Tat-systems were compared to standard CMV vectors in neona- 
tal rat cardiomyocytes (CMCs). PL in CMCs, CaZ+ uptake activity in CMC homogenates, 
and Ca2+ transients in intact CM&, were measured using standard methods, Luc activ- 
ity by luminometry. More than 65 % of CMCs were routinely expressing both TRE-trans- 
gene and rtTA vector. In the TRE-Luc system, basal transgene activity in the absence of 
Tet was not significantly above the background, whereas at 4OQ nglml Tet, Luc activity 
was 46 % above that of the CMV vector. Under maximal stimulation, the TRE-PLas vec- 
tor had simtlar effects as the CMV-Plas vector upon dose-and time-dependent reduction 
of PL-mRNA and protein, Ca2+ uptake activity, and Ca2+ transients. Both TRE-PLs vec- 
tor and TRE-Plas without Tet had no significant effects. Conclusions: Pharmacological 
control of vector-based PL-antisense-RNA expression may become a more flexible gene 
therapy approach to the improvement of diastolic dysfunction than the previously used 
CMV and ANF promotor vectors, allowing rapid adaptation to the hemodynamic situation. 
JACC 
ORAL CONTRIBUTIONS 
874 Heart Failure Insights From 
Fraction 
March 19,2003 
Ejection 
Wednesday, April 02, 2003, 8:30 a.m.-l 0:OO a.m. 
McCormick Place, Room S403 
8:30 a.m. 
674-l Relation Between Changes in Ejection Fraction Over 
Time and Subsequent Mortality and Morbidity in Val- 
HeFf 
lnderiit S. Anand, Maylene Wang. Riberto Latini, Lloyd Fisher, Yann Tong Chiang, Jay N. 
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Minnesota, Minneapolis, MN, lstituto di Ricerche Farmacologiche “Mario Negri”, Mitano. 
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Background: Left ventricular remodeling is considered an important determinant of pro- 
gression of heart failure (HF), and ejection fraction (EF) has consistently been shown to 
predict mortality and morbidity (M&M). Whether changes in EF over time correspond to 
subsequent changes in M&M has not been studied. Such a relationship would further 
strengthen the role of LV remodeling as a surrogate for events. Val-HeFT evaluated the 
efficacy of the ARB valsartan in patients with moderate and severe HF and measured EF 
in over 5000 patients at baseline and over 4500 patients during follow-up, and provided 
data for this study. Methods: Change in echocardiographically derived EF from baseline 
(BL) to 4, 12, and 24 months were analyzed in subgroups by quartiles for subsequent 
M&M. Risk ratio (RR) and 95% Cl were calculated for M&M in all patrents, irrespective of 
treatment using Cox regression, adjusting for baseline EF. Results: BL EF in quartrles 
showed a significant quartile-dependent increase in M&M risk (data not shown). 
Changes in EF from BL to 4 months also showed a signrficant and corresponding change 
in M&M. As compared with patients who had no or little change in EF over time (quartile 
2) patients whose EF decreased (quartile 1) showed a srgnificant increase in RR for 
M&M, whereas patients with an increase in EF (quartiles 3 & 4) showed a decrease in 
RR for M&M. Similar findings were seen for changes in EF at 12 and 24 months. Conclu- 
sions: These data further reinforce the role of EF as a significant surrogate marker in HF. 
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874-2 Hemodynamic Mechanisms of Ejection Fraction 
Improvement With Chronic Carvedilol Treatment in 
Heart Failure: Insights From Three-Dimensional 
Echocardiography 
Mathew S. Maurer, Daniel Burkhoff, Lyna El-Khoury Coffin, Donald L. King, Norma 
Medina. Madeline Yushak. Jonathan D. Sackner-Bernstein. Columbia Universitv. New 
York, NY, St. Luke’sRoosevelt Hospital, New York, NY 
Background. CarvedrIo is known to improve ejection fraction in patients wth CHF but the 
relative contributions of heart rate reduction, afterload reduction and positive inotropism 
to this beneficial effect are unknown. 
Methods. 32 patients (64+12 years old, 20 wth idiopathic and 12 with ischemic cardi- 
omyopathy) with NYHA II-111 underwent serial three dimensional echocardiogram (3DE) 
at baseline and 4 months after initiation of carvedilol. 3DE derived measures of LV vol- 
umes and mass were coupled with sphygmomanometic measurements of arterial pres- 
sures yielding estimates of chamber contractility (end-systolic pressure-volume ratio, 
Res, where PesSBP’O.S), effective arterial elastance (Ea, -TPR’GO/HR) and ventricular 
vascular coupling (EefRes). 
Results. EF increased by 6 f 6 percentage points (from 26+6% to 32*9%, p<O.OOOl). 
The change in EF was correlated with changes in stroke volume (w0.66. p<O.OOOl) but 
not wth changes in end diastolic volume (r=.09, p=NS). Pressure-volume based analysis 
show that Res increased from 0.72*0.39 to 0.60+0.36 mmHg/ml (p=O.O3). Ea decreased 
from 2.liO.6 to 1.7kO.5 mmHg/ml (pcO.001). which was due to a significant decrease in 
HR (from 63+11 to 65+6 bpm, p<O.OOl) with no significant change in TPR (1.3kO.4 vs 
1.3iO.4 ml/mmHglmin). Ea/Res improved from 3.4&1.5 to 2.5il.3 (pcO.001). 
Conclusions: Improved chamber contractility (indexed by increased Res) and decreased 
